Cited by 137Diabetes Treatment and ManagementCardiovascular Function and Risk FactorsHeart Failure Treatment and Management

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial

Open access

Bizino, Maurice B., Jazet, Ingrid M., Westenberg, Jos J. M., van Eyk, Huub J., Paiman, Elisabeth H. M., Smit, Jan W. A., Lamb, Hildebrandus J.·2019·Cardiovascular Diabetology

DOI 10.1186/s12933-019-0857-6PMC PMC6492440

Open this paper in CoChat — free account Open PDF

Abstract

Abstract Background Liraglutide is an antidiabetic agent with cardioprotective effect. The purpose of this study is to test efficacy of liraglutide to improve diabetic cardiomyopathy in patients with diabetes mellitus type 2 (DM2) without cardiovascular disease. Methods Patients with DM2 were randomly assigned to receive liraglutide 1.8 mg/day or placebo in this double-blind trial of 26 weeks. Primary outcome measures were LV diastolic function (early (E) and late (A) transmitral peak flow rate, E/A ratio, early deceleration peak (Edec), early peak mitral annular septal tissue velocity (Ea) and estimated LV filling pressure (E/Ea), and systolic function (stroke volume, ejection fraction, cardiac output, cardiac index and peak ejection rate) assessed with CMR. Intention-to-treat analysis of between-group differences was performed using ANCOVA. Mean estimated treatment differences (95% confidence intervals) are reported. Results 23 patients were randomized to liraglutide and 26 to placebo. As compared with placebo, liraglutide significantly reduced E (− 56 mL/s (− 91 to − 21)), E/A ratio (− 0.17 (− 0.27 to − 0.06)), Edec (− 0.9 mL/s 2 * 10 −3 (− 1.3 to − 0.2)) and E/Ea (− 1.8 (− 3.0 to − 0.6)), without affecting A (3 mL/s (− 35 to 41)) and Ea (0.4 cm/s (− 0.9 to 1.4)). Liraglutide reduced stroke volume (− 9 mL (− 16 to − 2)) and ejection fraction (− 3% (− 6 to − 0.1)), but did not change cardiac output (− 0.4 L/min (− 0.9 to 0.2)), cardiac index (− 0.1 L/min/m 2 (− 0.4 to 0.1)) and peak ejection rate (− 46 mL/s (− 95 to 3)). Conclusions Liraglutide reduced early LV diastolic filling and LV filling pressure, thereby unloading the left ventricle. LV systolic function reduced and remained within normal range. Future studies are needed to investigate if liraglutide-induced left ventricular unloading slows progression of diabetic cardiomyopathy into symptomatic stages. Trial registration ClinicalTrials.gov: NCT01761318.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/s12933-019-0857-6

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Trial profile. Patients were randomized with stratification according to sex and insulin use. One patient in liraglutide group withdrew consent before he ever received study drug. This patient was therefore not included in intention-to-treat analysis. In another patient assigned to liraglutide, withdrawal had taken place upon repeated hypoglycaemic events (on further examination this patient had positive anti-glutamic acid decarboxylase autoantibody titer and undetectable c-peptide levels consistent with type 1 diabetes mellitus). In the placebo group, one patient was lost to follow-up because he was in detention. All other patients reached end of study. ITT intention-to-treatCC BY · PubMed Central

Fig. 2 LV diastolic function. Bar graphs of MR-derived indices of LV diastolic function. Blue bars indicate baseline measurement and red bars follow-up. Ea reflects the early peak longitudinal annular motion that is dependent on LV myocardial relaxation. E/Ea is the MR estimate of LV filling pressure. NS not significantCC BY · PubMed Central

Fig. 3 LV systolic function. Bar graphs of MRI-derived indices of systolic function. Blue bars indicate baseline measurement and red bars follow-up. In the liraglutide group stroke volume decreased, whereas cardiac index remained unchanged because of the increased heart rate. Bpm beats per minuteCC BY · PubMed Central

Fig. 4 Pressure-volume relation. The LV filling pressure estimate E/Ea plotted against LV end-diastolic pressure (LVEDV). Liraglutide treatment (squares; blue = baseline, red = follow-up) results in a lower E/Ea and LVEDV, whereas placebo treated patients (circles; blue = baseline, red = follow-up) have higher E/Ea and LVEDV at follow-up then at baseline. Note that the shift in pressure volume curve is in opposite directions for liraglutide versus placebo. There was a tendency towards improved compliance in the liraglutide groupCC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Burden of Systolic and Diastolic Ventricular Dysfunction in the Community
Redfield, M. M., Jacobsen, S. J., Burnett, J. C. J., Mahoney, D. W., Bailey, K. R., & Rodeheffer, R. J. (2003) · JAMA · doi:10.1001/jama.289.2.194 · Cited by 2,989
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
MacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn153 · Cited by 694
Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654
Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort
Petersen, S. E., Aung, N., Sanghvi, M. M., Zemrak, F., Fung, K., Paiva, J. M., Francis, J. M., Khanji, M. Y., Lukaschuk, E. I., Lee, A. M., et al. (2016) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-017-0327-9 · Cited by 601
Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509

Show all 42 references

Sorted by citations

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence
Tan, Y., Zhang, Z., Zheng, C., Wintergerst, K. A., Keller, B. B., & Cai, L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0339-2 · Cited by 862
The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
Withaar, C., Meems, L. M. G., Markousis-Mavrogenis, G., Boogerd, C. J., Silljé, H. H. W., Schouten, E. M., Dokter, M. M., Voors, A. A., Westenbrink, B. D., Lam, C. S. P., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa256 · Cited by 223
Autophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy
Dewanjee, S., Vallamkondu, J., Kalra, R. S., John, A. A., Reddy, P. H., & Kandimalla, R. J. L. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101338 · Cited by 178
Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization
Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139
Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: A pre-specified secondary study on ectopic fat accumulation
Bizino, M. B., Jazet, I. M., de Heer, P., van Eyk, H. J., Dekkers, I. A., Rensen, P. C. N., Paiman, E. H. M., Lamb, H. J., & Smit, J. W. (2020) · Diabetologia · doi:10.1007/s00125-019-05021-6 · Cited by 123
Self-citation
Diabetic cardiomyopathy: Clinical phenotype and practice
Zhao, X., Liu, S., Wang, X., Chen, Y., Pang, P., Yang, Q., Lin, J., Deng, S., Shen-tao, W., Fan, G., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032268 · Cited by 128
Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction
Salah, H. M., Pandey, A., Soloveva, A. E., Abdelmalek, M. F., Diehl, A. M., Moylan, C. A., Wegermann, K., Rao, V. N., Hernandez, A. F., Tedford, R. J., et al. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.07.010 · Cited by 110
A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients
van Eyk, H. J., Paiman, E. H. M., Bizino, M. B., de Heer, P., Geelhoed-Duijvestijn, P. H., Kharagjitsingh, A. V., Smit, J. W. A., Lamb, H. J., Rensen, P. C. N., & Jazet, I. M. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0890-5 · Cited by 90
The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF
Withaar, C., Meems, L. M. G., Nollet, E. E., Schouten, E. M., Schroeder, M. A., Knudsen, L. B., Niss, K., Madsen, C. T., Hoegl, A., Mazzoni, G., et al. (2023) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2023.05.012 · Cited by 74
GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1β-induced metabolic disturbance and mitochondrial dysfunction
Zhang, L., Tian, J., Diao, S., Zhang, G., Xiao, M., & Chang, D. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109252 · Cited by 73
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 70
A comprehensive survey on low-cost ECG acquisition systems: Advances on design specifications, challenges and future direction
Faruk, N., Abdulkarim, A., Emmanuel, I., Folawiyo, Y. Y., Adewole, K. S., Mojeed, H. A., Oloyede, A. A., Olawoyin, L. A., Sikiru, I. A., Nehemiah, M., et al. (2021) · Journal of Applied Biomedicine · doi:10.1016/j.bbe.2021.02.007 · Cited by 68
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
Zhang, D.-P., Xu, L., Wang, L., Wang, H.-J., & Jiang, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0987-x · Cited by 65
Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
Longato, E., Camillo, B. D., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01049-w · Cited by 58
The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
Hullon, D., Subeh, G. K., Volkova, Y., Janiec, K., Trach, A., & Mnevets, R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02607-w · Cited by 59
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?
Lee, M. M. Y., Petrie, M. C., McMurray, J. J. V., & Sattar, N. A. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311904 · Cited by 57
Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies
Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., Giugliano, D., & Esposito, K. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01090-9 · Cited by 54
Epicardial Fat Expansion in Diabetic and Obese Patients with Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype
Elsanhoury, A., Nelki, V., Kelle, S., Van Linthout, S., & Tschöpe, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.720690 · Cited by 51
Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials
Ussher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E. (2022) · Diabetes · doi:10.2337/dbi20-0049 · Cited by 51
Cardiovascular Determinants of Aerobic Exercise Capacity in Adults With Type 2 Diabetes
Gulsin, G. S., Henson, J. J., Brady, E. M., Sargeant, J. A., Wilmot, E. G., Athithan, L., Htike, Z. Z., Marsh, A.-M., Biglands, J. D., Kellman, P., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0706 · Cited by 49
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
Yang, C., Yang, C., Ou, H., & Kuo, S. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01053-0 · Cited by 47
Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes
Bojer, A. S., Sørensen, M. H., Vejlstrup, N. G., Goetze, J. P., Gæde, P., & Madsen, P. L. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01160-y · Cited by 43
Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Grover, A., Sharma, K., Gautam, S., Gautam, S., Gulati, M., & Singh, S. K. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666201103144231 · Cited by 47
Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Liu, H., Fu, D., & Daoquan, P. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.12.006 · Cited by 42
Targeting mitochondrial quality control for diabetic cardiomyopathy: Therapeutic potential of hypoglycemic drugs
Zhou, Y., Suo, W., Zhang, X., Liang, J., Zhao, W., Wang, Y., Li, H., & Ni, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115669 · Cited by 43
Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double‐Blind, Randomized, Placebo‐Controlled Trial
Paiman, E. H. M., van Eyk, H. J., van Aalst, M., Bizino, M. B., van der Geest, R. J., Westenberg, J. J. M., Geelhoed-Duijvestijn, P. H. L. M., Kharagjitsingh, A. V., Rensen, P. C. N., Smit, J. W. A., et al. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27009 · Cited by 42
Comparison of Sodium–Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35
Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials
Karakasis, P., Vlachos, K. G., Antoniadis, A. P., Siontis, K. C., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156463 · Cited by 48
Heart rate variability features from nonlinear cardiac dynamics in identification of diabetes using artificial neural network and support vector machine
Aggarwal, Y., Das, J., Mazumder, P. M., Kumar, R., & Sinha, R. K. (2020) · Journal of Applied Biomedicine · doi:10.1016/j.bbe.2020.05.001 · Cited by 41
Catalpol ameliorates doxorubicin‑induced inflammation and oxidative stress in H9C2 cells through PPAR‑γ activation
Jiang, Y., & Zhang, Q. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8743 · Cited by 36
MOTS-c and Exercise Restore Cardiac Function by Activating of NRG1-ErbB Signaling in Diabetic Rats
Li, S., Wang, M., Ma, J., Pang, X., Yuan, J., Pan, Y., Fu, Y., & Laher, I. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.812032 · Cited by 36
A randomized, open‐label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes
Webb, D. R., Htike, Z. Z., Swarbrick, D. J., Brady, E. M., Gray, L. J., Biglands, J. D., Gulsin, G. S., Henson, J. J., Khunti, K., McCann, G. P., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14023 · Cited by 34
Liraglutide Attenuates Myocardial Fibrosis via Inhibition of AT1R-Mediated ROS Production in Hypertensive Mice
Chen, P., Yang, F., Wang, W., Li, X., Liu, D., Zhang, Y., Yin, G., Lv, F., Guo, Z., Mehta, J. L., et al. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420942007 · Cited by 31
Ferroptosis in diabetic cardiomyopathy: from its mechanisms to therapeutic strategies
Tian, M., Huang, X., Li, M., Lou, P., Ma, H., Jiang, X., Zhou, Y., & Liu, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1421838 · Cited by 35
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 40
The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy
Gopal, K., Chahade, J. J., Kim, R., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.603247 · Cited by 32
Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
Kumarathurai, P., Sajadieh, A., Anholm, C., Kristiansen, O. P., Haugaard, S. B., & Nielsen, O. W. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01205-2 · Cited by 31
Renal sinus fat volume in type 2 diabetes mellitus is associated with glycated hemoglobin and metabolic risk factors
Lin, L., Dekkers, I. A., Huang, L., Tao, Q., Paiman, E. H. M., Bizino, M. B., Jazet, I. M., & Lamb, H. J. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107973 · Cited by 31
Mitochondrial energy metabolism in diabetic cardiomyopathy: Physiological adaption, pathogenesis, and therapeutic targets
Ye, W., Han, K., Xie, M., Li, S., Chen, G., Wang, Y., & Li, T. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003075 · Cited by 32
Phenotyping diabetic cardiomyopathy in Europeans and South Asians
Paiman, E. H. M., van Eyk, H. J., Bizino, M. B., Dekkers, I. A., de Heer, P., Smit, J. W. A., Jazet, I. M., & Lamb, H. J. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0940-z · Cited by 30
Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues
Longo, M., Scappaticcio, L., Cirillo, P., Maio, A., Carotenuto, R. M., Maiorino, M. I., Bellastella, G., & Esposito, K. (2022) · Biomolecules · doi:10.3390/biom12020272 · Cited by 30
Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
Ida, S., Kaneko, R., Imataka, K., Ôkubo, K., Shirakura, Y., Azuma, K., Fujiwara, R., Takahashi, H., & Murata, K. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09936-w · Cited by 28
Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
Belli, M., Barone, L., Bellia, A., Sergi, D., Lecis, D., Prandi, F. R., Milite, M., Galluccio, C., Muscoli, S., Romeo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314598 · Cited by 29
The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis
Avogaro, A., Azzolina, D., Gregori, D., de Kreutzenberg, S., Fadini, G. P., & Mannucci, E. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.03.032 · Cited by 27
Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials
Wong, S. Y., Lee, A. R. Y. B., Sia, A. H. J., Wo, Y. J., Teo, Y. H., Teo, Y. N., Syn, N. L. X., Ong, C. C., Teo, L., Yeo, T., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07360-w · Cited by 26
Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
King, N. E., & Brittain, E. L. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12028 · Cited by 28
Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators
García‐Vega, D., González‐Juanatey, J. R., & Eirás, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147886 · Cited by 26
Glucagon‐like peptide‐1 receptor agonist treatment of high carbohydrate intake‐induced metabolic syndrome provides pleiotropic effects on cardiac dysfunction through alleviations in electrical and intracellular Ca2+ abnormalities and mitochondrial dysfunction
Durak, A. T., Akkuş, E., Canpolat, A. G., Tuncay, E., Çorapçıoğlu, D., & Turan, B. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13590 · Cited by 22
Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity
Dhore-Patil, A., Thannoun, T., Samson, R., & Jemtel, T. H. L. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.785879 · Cited by 27
New antidiabetic therapy and HFpEF: light at the end of tunnel?
Tadić, M., Sala, C., Saeed, S., Grassi, G. M., Mancia, G., Rottbauer, W., & Cuspidi, C. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10106-9 · Cited by 23
The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis
Zhang, Y., Yang, D., Jia, Q., Yan, J., & An, F. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15557 · Cited by 22
Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life
Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y., & Soloveva, A. E. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.05 · Cited by 23
Pulmonary hypertension associated to left heart disease: Phenotypes and treatment
Madonna, R., Biondi, F., Ghelardoni, S., D'Alleva, A., Quarta, S., & Massaro, M. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.07.030 · Cited by 20
Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth?
Nesti, L., & Tricò, D. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.818 · Cited by 19
Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE
Liang, B., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01088-3 · Cited by 19
The Effect of Glycemic Control on Renal Triglyceride Content Assessed by Proton Spectroscopy in Patients With Type 2 Diabetes Mellitus: A Single-Center Parallel-Group Trial
Dekkers, I. A., Bizino, M. B., Paiman, E. H. M., Smit, J. W. A., Jazet, I. M., de Vries, A. P. J., & Lamb, H. J. (2020) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2020.09.006 · Cited by 20
Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss
Simeone, P., Tripaldi, R., Michelsen, A. E., Ueland, T., Liani, R., Ciotti, S., Birkeland, K. I., Gulseth, H. L., Castelnuovo, A. F. D., Cipollone, F., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01469-w · Cited by 22
New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes
Wronka, M., Krzemińska, J., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · Biomedicines · doi:10.3390/biomedicines11041159 · Cited by 22
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond
Zaher, W., Rocca, D. G. D., Pannone, L., Bovéda, S., de Asmundis, C., Chierchia, G., & Sorgente, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051316 · Cited by 18
Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction
Yagi, K., Imamura, T., Tada, H., Chujo, D., Liu, J., Shima, Y., Ohbatake, A., Miyamoto, Y., Okazaki, S., Ito, N., et al. (2021) · Journal of Diabetes Research · doi:10.1155/2021/8838026 · Cited by 18
Liraglutide Ameliorates Cerebral Ischemia in Mice via Antipyroptotic Pathways
Yang, L., Cheng, J., Shi, G., Zhang, C., Du, Y., Chen, L., Qiao, H., Chen, R., & Zhang, X. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03574-4 · Cited by 18
Glimepiride use is associated with reduced cardiovascular mortality in patients with type 2 diabetes and chronic heart failure: a prospective cohort study
He, W., Yuan, G., Han, Y., Yan, Y., Li, G., Zhao, C., Shen, J., Jiang, X., Chen, C., Ni, L., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac312 · Cited by 18
Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats
Bajić, Z., Šobot, T., Uletilović, S., Mandić-Kovačević, N., Cvjetković, T., Maličević, U., Đukanović, Đ., Duran, M., Vesić, N., Avram, S., et al. (2023) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2022-0534 · Cited by 18
Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review
Gómez‐Pérez, A. M., Damas-Fuentes, M., Cornejo-Pareja, I. M., & Tinahones, F. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194497 · Cited by 18
Research status and trends of the diabetic cardiomyopathy in the past 10 years (2012–2021): A bibliometric analysis
Wang, S., Tian, C., Gao, Z., Zhang, B., & Zhao, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1018841 · Cited by 17
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Kreiner, F. F., Hovingh, G. K., & von Scholten, B. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.983961 · Cited by 17
A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction
Liu, Z., Bian, N., Wu, S., Fan, Y., Li, H., Yu, J. Y., Guo, J., & Chen, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1019120 · Cited by 17
Comparison of Glucose Control by Added Liraglutide to Only Insulin Infusion in Diabetic Patient Undergoing Cardiac Surgery
Sindhvananda, W., Poopuangpairoj, W., Jaiprasat, T., & Ongcharit, P. (2023) · Annals of Cardiac Anaesthesia · doi:10.4103/aca.aca_214_20 · Cited by 16
Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study
Basile, P., Guaricci, A. I., Piazzolla, G., Volpe, S., Vozza, A., Benedetto, M., Carella, M. C., Santoro, D., Monitillo, F., Baggiano, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041586 · Cited by 16
Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
Cersosimo, A., Salerno, N., Sabatino, J., Scatteia, A., Bisaccia, G., Rosa, S. D., Dellegrottaglie, S., Bucciarelli‐Ducci, C., Torella, D., & Leo, I. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02181-7 · Cited by 17
Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance
Симаненкова, А. В., Минасян, С. М., Каронова, Т. Л., Vlasov, T. D., Тимкина, Н. В., Shpilevaya, O., Константиновна, Х. А., Shimshilashvili, A., Тимофеева, В. А., Samsonov, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-86132-2 · Cited by 16
Current challenges in the treatment of cardiac fibrosis: Recent insights into the sex‐specific differences of glucose‐lowering therapies on the diabetic heart: IUPHAR Review 33
Sharma, A., Blasio, M. J. D., & Ritchie, R. H. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15820 · Cited by 14
The role and therapeutic potential of macrophages in the pathogenesis of diabetic cardiomyopathy
Zhang, S., Zhu, X., Chen, Y., Wen, Z., Shi, P., & Ni, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1393392 · Cited by 16
Clinical Update in Heart Failure with Preserved Ejection Fraction
Krittanawong, C., Britt, W., Rizwan, A. M., Siddiqui, R., Khawaja, M., Khan, R., Joolharzadeh, P., Newman, N. A., Rivera, M. R. R., & Tang, W. H. W. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00679-5 · Cited by 17
Incidence of idiopathic cardiomyopathy in patients with type 2 diabetes in Taiwan: age, sex, and urbanization status-stratified analysis
Chen, H.-F., Chang, Y., Lo, H.-J. L., Isfandiari, M. A., Martini, S., Hou, W., & Li, C. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01144-y · Cited by 14
Metabolic improvement with short‐term, glucagon‐like peptide‐1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial
Bojer, A. S., Sørensen, M. H., Bjerre, J., Gæde, P., Vejlstrup, N. G., & Madsen, P. L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14480 · Cited by 14
The Role of Mitochondria in Metabolic Syndrome–Associated Cardiomyopathy
Li, J., Li, J., Chen, Y., Hu, W., Gong, X., Qiu, H., Chen, H., Xin, Y., & Li, H. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9196232 · Cited by 17
Altered high‐density lipoprotein composition is associated with risk for complications in type 2 diabetes mellitus in South Asian descendants: A cross‐sectional, case‐control study on lipoprotein subclass profiling
Yuan, L., Li‐Gao, R., Verhoeven, A., van Eyk, H. J., Bizino, M. B., Rensen, P. C. N., Giera, M. A., Jazet, I. M., Lamb, H. J., Rabelink, T. J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15118 · Cited by 13
Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes
Patel, K. V., Chunawala, Z. S., Verma, S., Segar, M. W., Garcia, K. R., Ndumele, C. E., Wang, T. J., Januzzi, J. L., Bayés‐Genís, A., Butler, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.004 · Cited by 14
Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review
Widiarti, W., Sukmajaya, A. C., Nugraha, D., & Alkaff, F. F. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.04.005 · Cited by 13
Differences in Inflammatory Pathways Between Dutch South Asians vs Dutch Europids With Type 2 Diabetes
Straat, M. E., Martínez‐Téllez, B., van Eyk, H. J., Bizino, M. B., van Veen, S., Vianello, E., Stienstra, R., Ottenhoff, T. H. M., Lamb, H. J., Smit, J. W. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac598 · Cited by 12
Type 2 diabetes and cardiovascular disease: risk reduction and early intervention
Hinnen, D., Kruger, D. F., & MAGWIRE, M. L. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2126235 · Cited by 19
Efficacy and Safety of Tirzepatide Compared with GLP-1 RAs in Patients with Type 2 Diabetes Treated with Basal Insulin: A Network Meta-analysis
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 12
HFpEF as the predominant and underrecognized heart failure phenotype in type 2 diabetes: evidence from the DIABET-IC study
Gil, P., Gimeno-Orna, J. A., Padial, L. R., Muñiz, J., Barrios, V., Anguita, M. P., & Pérez, A. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02995-z · Cited by 11
The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome
Wójcicka, G., Pradiuch, A., Fornal, E., Stachniuk, A., Korolczuk, A., Marzec‐Kotarska, B., Nikolaichuk, H., Czechowska, G., Kozub-Pędrak, A., Trzpil, A., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115637 · Cited by 10
Transient receptor potential vanilloid type 1: cardioprotective effects in diabetic models
Bao, J., Gao, Z., Hu, Y., Ye, L., & Wang, L. (2023) · Channels · doi:10.1080/19336950.2023.2281743 · Cited by 9
Subclinical HMOD in Hypertension: Left Ventricular Diastolic Dysfunction
Bertacchini, F., Rosei, C. A., Buso, G., Cappellini, S., Stassaldi, D., Aggiusti, C., Salvetti, M., Paini, A., Ciuceis, C. D., & Muiesan, M. L. (2022) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-022-00548-z · Cited by 9
Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis
Huang, Y., Xu, X.-Z., Liu, J., Wang, P.-Y., Wang, X., Feng, H., Liu, C., & Han, X. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03324-6 · Cited by 9
Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies
Bizino, M. B., Jazet, I. M., van Eyk, H. J., Rensen, P. C. N., Geelhoed-Duijvestijn, P. H. L. M., Kharagjitsingh, A. V., Paiman, E. H. M., Smit, J. W. A., & Lamb, H. J. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01635-0 · Cited by 8
MR Assessed Changes of Renal Sinus Fat in Response to Glucose Regulation in West European and South Asian Patients With Type 2 Diabetes
Lin, L., Dekkers, I. A., Tao, Q., Paiman, E. H. M., Bizino, M. B., Jazet, I. M., & Lamb, H. J. (2023) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29174 · Cited by 8
Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow?
Masarone, D., Valente, F., Verrengia, M., Contaldi, C., Palma, V. D., Falco, L., Catapano, D., & di Lorenzo, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226867 · Cited by 7
Therapeutic Potential of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction (HFpEF) in Obese Patients
Patel, R., Kokori, E., Olatunji, G. D., Adejumo, F. A., Ukah, J. D., Babalola, A. E., Ndakotsu, A., Abraham, I. C., & Aderinto, N. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00704-1 · Cited by 7
Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review
Nikolaidou, A., Ventoulis, I., Karakoulidis, G., Anastasiou, V., Daios, S., Papadopoulos, S.-F., Didagelos, M., Parissis, J., Karamitsos, T. D., Kotsa, K., et al. (2024) · Medicina · doi:10.3390/medicina60060912 · Cited by 9
Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials
Xia, W., Yu, H., Lei, X., & Wen, P. (2024) · Medicine · doi:10.1097/md.0000000000037432 · Cited by 7
Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort
van Eyk, H. J., Blauw, L. L., Bizino, M. B., Wang, Y., van Dijk, K. W., de Mutsert, R., Smit, J. W. A., Lamb, H. J., Jazet, I. M., & Rensen, P. C. N. (2019) · Scientific Reports · doi:10.1038/s41598-019-45593-2 · Cited by 7
Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy—Challenges and Prospectives
Khattab, E., Kyriakou, M., Leonidou, E., Sokratous, S., Mouzarou, A., Myrianthefs, M. M., & Kadoglou, N. P. E. (2025) · Pharmaceuticals · doi:10.3390/ph18010134 · Cited by 7
Ethnic Disparities in Lipid Metabolism and Clinical Outcomes between Dutch South Asians and Dutch White Caucasians with Type 2 Diabetes Mellitus
Yuan, L., Verhoeven, A., Blomberg, N., van Eyk, H. J., Bizino, M. B., Rensen, P. C. N., Jazet, I. M., Lamb, H. J., Rabelink, T. J., Giera, M. A., et al. (2024) · Metabolites · doi:10.3390/metabo14010033 · Cited by 6
Effect of glucose regulation on renal parenchyma and sinus fat volume in patients with type 2 diabetes
Lin, L., Dekkers, I. A., Tao, Q., Paiman, E. H. M., Bizino, M. B., Jazet, I. M., & Lamb, H. J. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101408 · Cited by 6
Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit
Thomas, J., Dagan, M., Wang, B. H., Gutman, S., & Kaye, D. M. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013279 · Cited by 8

Authors: Bizino, M. B., Jazet, I. M., Westenberg, J. J. M., van Eyk, H. J., Paiman, E. H. M., Smit, J. W. A., & Lamb, H. J.
Affiliations: Leiden University Medical Center (NL)
Corresponding author: Bizino, Maurice B.
ORCID: Bizino, Maurice B.
Jazet, Ingrid M.
Westenberg, Jos J. M.
Paiman, Elisabeth H. M.
Venue: Cardiovascular Diabetology
Publisher: Springer Science and Business Media LLC
Published: 2019-04-30
Volume: 18
Issue: 1
Pages: 55-55
ISSN: 1475-2840 (ISSN-L)
DOI: 10.1186/s12933-019-0857-6
PMC: PMC6492440
OpenAlex: W2946264273
Cited by: 137
References: 42
Citations by year: 2026: 8 · 2025: 12 · 2024: 21 · 2023: 20 · 2022: 26 · 2021: 18 · 2020: 25 · 2019: 7
FWCI: 15.41
Type: journal article
Language: en
Update notices: correction (2019-08-09)
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: Cardiovascular Diabetology (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Radboud Repository (Radboud University) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
Leiden Repository (Leiden University) (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Radboud Repository (Radboud University) (submittedVersion)
Funders: Novo Nordisk (NA)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords: liraglutide, type 2 diabetes, diabetic cardiomyopathy, left ventricular diastolic function, left ventricular filling pressure, left ventricular systolic function, cardiac magnetic resonance, GLP-1 receptor agonists, cardioprotection, stroke volume, ejection fraction, cardiac unloading, cardiovascular risk reduction
MeSH terms: Liraglutide, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Magnetic Resonance Imaging, Male, Middle Aged, Netherlands, Stroke Volume, Time Factors, Biomarkers, Ventricular Function, Left, Treatment Outcome, Ventricular Pressure, Ventricular Dysfunction, Left, Recovery of Function, Young Adult, Diabetic Cardiomyopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks